{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:54:11Z","timestamp":1790819651048,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Adrenocorticotropic hormone (ACTH) has shown efficacy as primary and secondary therapy for nephrotic syndrome due to membranous nephropathy. The data on using ACTH to treat idiopathic FSGS are limited. This report describes our experience using ACTH for nephrotic syndrome due to idiopathic FSGS in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      Twenty-four patients with nephrotic syndrome from idiopathic FSGS were treated with ACTH gel at two academic medical centers between 2009 and 2012, either as part of investigator-initiated pilot studies (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =16) or by prescription for treatment-resistant FSGS (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =8). The primary outcome was remission of proteinuria. The median dose of ACTH was 80 units injected subcutaneously twice weekly. Treatment durations were not uniform.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-two patients had received immunosuppression (mean, 2.2 medications) before ACTH therapy. Six patients had steroid-dependent and 15 had steroid-resistant FSGS. At the time of ACTH initiation, the median serum creatinine (interquartile range) was 2.0 (1.1\u20132.7) mg\/dl, estimated GFR was 36 (28\u201378) ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , and urine protein-to-creatinine ratio was 4595 (2200\u20138020) mg\/g. At the end of ACTH therapy, 7 of 24 patients (29%) experienced remission (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =2 complete remissions,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =5 partial remissions). All remitters had steroid-resistant (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =5) or steroid-dependent (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =2) FSGS. Two responders relapsed during the follow-up period (mean \u00b1 SD, 70\u00b131 weeks). Adverse events occurred in 21 of 24 patients, including one episode of new-onset diabetes that resolved after stopping ACTH and two episodes of AKI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Response to ACTH treatment among steroid-resistant or steroid-dependent patients with FSGS is low, but ACTH gel may be a viable treatment option for some patients with resistant nephrotic syndrome due to idiopathic FSGS. Further research is necessary to determine which patients will respond to therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02840313","type":"journal-article","created":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:03:12Z","timestamp":1378425792000},"page":"2072-2081","source":"Crossref","is-referenced-by-count":83,"title":["Treatment of Idiopathic FSGS with Adrenocorticotropic Hormone Gel"],"prefix":"10.2215","volume":"8","author":[{"given":"Jonathan","family":"Hogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kshama","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro A.","family":"Canetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya K.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20230811","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1523-1755.2004.00834.x","article-title":"Epidemiologic data of primary glomerular diseases in western France.","volume":"66","author":"Simon","year":"2004","journal-title":"Kidney Int"},{"key":"R2-8-20230811","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/ndt\/16.7.1364","article-title":"The incidence of biopsy-proven glomerulonephritis in Australia.","volume":"16","author":"Briganti","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"R3-8-20230811","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0272-6386(95)90437-9","article-title":"Increasing incidence of focal-segmental glomerulosclerosis among adult nephropathies: A 20-year renal biopsy study.","volume":"26","author":"Haas","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R4-8-20230811","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0272-6386(00)70258-7","article-title":"Changing incidence of glomerular diseases in adults.","volume":"35","author":"Braden","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R5-8-20230811","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2215\/CJN.00710805","article-title":"Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study.","volume":"1","author":"Swaminathan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R7-8-20230811","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: Presentation, prognosis, and response to therapy of the histologic variants.","volume":"15","author":"Chun","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R8-8-20230811","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission.","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R9-8-20230811","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis.","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"key":"R10-8-20230811","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","article-title":"A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.","volume":"43","author":"Ponticelli","year":"1993","journal-title":"Kidney Int"},{"key":"R11-8-20230811","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.ajkd.2003.09.027","article-title":"Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis.","volume":"43","author":"Heering","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R12-8-20230811","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ki.2011.195","article-title":"Clinical trial of focal segmental glomerulosclerosis in children and young adults.","volume":"80","author":"Gipson","year":"2011","journal-title":"Kidney Int"},{"key":"R13-8-20230811","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/ndt\/17.4.655","article-title":"Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up.","volume":"17","author":"Segarra","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R14-8-20230811","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000168042","article-title":"Ciclosporin in the treatment of nephrosis. Minimal change disease and focal-segmental glomerulosclerosis.","volume":"9","author":"Meyrier","year":"1989","journal-title":"Am J Nephrol"},{"key":"R15-8-20230811","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5414\/CNP65393","article-title":"Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome.","volume":"65","author":"Westhoff","year":"2006","journal-title":"Clin Nephrol"},{"key":"R16-8-20230811","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.ajkd.2009.02.018","article-title":"Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.","volume":"54","author":"Li","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R17-8-20230811","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ndt\/17.11.2011","article-title":"Mycophenolatemofetil in the treatment of resistant idiopathic nephrotic syndrome.","volume":"17","author":"Day","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"R18-8-20230811","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00467-003-1174-5","article-title":"Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade.","volume":"18","author":"Montan\u00e9","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"R19-8-20230811","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5414\/CNP62405","article-title":"Mycophenolatemofetil in the treatment of focal segmental glomerulosclerosis.","volume":"62","author":"Cattran","year":"2004","journal-title":"Clin Nephrol"},{"key":"R20-8-20230811","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","article-title":"Long-term outcome in children and adults with classic focal segmental glomerulosclerosis.","volume":"32","author":"Cattran","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R21-8-20230811","first-page":"53","article-title":"The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study.","volume":"36","author":"Banfi","year":"1991","journal-title":"Clin Nephrol"},{"key":"R22-8-20230811","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis.","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am SocNephrol"},{"key":"R23-8-20230811","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/ajkd.1998.v32.pm9708606","article-title":"Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys.","volume":"32","author":"Feld","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R24-8-20230811","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.1951.03670290009004","article-title":"Effect of corticotropin (ACTH) on children with the nephrotic syndrome.","volume":"147","author":"Rapoport","year":"1951","journal-title":"J Am Med Assoc"},{"key":"R25-8-20230811","first-page":"341","article-title":"Effect of ACTH in children with the nephrotic syndrome.","volume":"9","author":"Barnett","year":"1952","journal-title":"Pediatrics"},{"key":"R26-8-20230811","first-page":"1290","article-title":"Melanocortin 1 receptor agonists reduce proteinuria.","volume":"21","author":"Lindskog","year":"2010","journal-title":"J Am SocNephrol"},{"key":"R27-8-20230811","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/ndt\/gfh110","article-title":"ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses.","volume":"19","author":"Berg","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R28-8-20230811","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ajkd.2005.10.016","article-title":"A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy.","volume":"47","author":"Ponticelli","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R29-8-20230811","doi-asserted-by":"crossref","first-page":"637","DOI":"10.5414\/CNP71637","article-title":"Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24.","volume":"71","author":"Rauen","year":"2009","journal-title":"Clin Nephrol"},{"key":"R30-8-20230811","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/DDDT.S17521","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel.","volume":"5","author":"Bomback","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"R31-8-20230811","first-page":"91","article-title":"Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH).","volume":"12","author":"Bomback","year":"2011","journal-title":"Discov Med"},{"key":"R32-8-20230811","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: A prospective trial.","volume":"36","author":"Bomback","year":"2012","journal-title":"Am J Nephrol"},{"key":"R33-8-20230811","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","article-title":"Pathologic classification of focal segmental glomerulosclerosis: A working proposal.","volume":"43","author":"D\u2019Agati","year":"2004","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201312000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:37:12Z","timestamp":1786369032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201312000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02840313","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}